 Connection
Kevin Lillehei to Cell Line, Tumor
This is a "connection" page, showing publications Kevin Lillehei has written about Cell Line, Tumor.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.092 |
|
|
|
-
Nguyen KN, Graner AN, Fringuello AR, Zizzo Z, Valenzuela L, Anyanwu K, Lillehei KO, Youssef AS, Guzman S, Coughlan C, Graner MW. Extracellular Vesicles from a Novel Chordoma Cell Line, ARF-8, Promote Tumorigenic Microenvironmental Changes When Incubated with the Parental Cells and with Human Osteoblasts. Int J Mol Sci. 2024 Nov 27; 25(23).
Score: 0.034
-
Liu Y, Ng K, Lillehei KO. Time course analysis and modulating effects of established brain tumor on active-specific immunotherapy. Neurosurg Focus. 2000 Dec 15; 9(6):e3.
Score: 0.026
-
Kiseljak-Vassiliades K, Xu M, Mills TS, Smith EE, Silveira LJ, Lillehei KO, Kerr JM, Kleinschmidt-DeMasters BK, Wierman ME. Differential somatostatin receptor (SSTR) 1-5 expression and downstream effectors in histologic subtypes of growth hormone pituitary tumors. Mol Cell Endocrinol. 2015 Dec 05; 417:73-83.
Score: 0.018
-
Xu M, Knox AJ, Michaelis KA, Kiseljak-Vassiliades K, Kleinschmidt-DeMasters BK, Lillehei KO, Wierman ME. Reprimo (RPRM) is a novel tumor suppressor in pituitary tumors and regulates survival, proliferation, and tumorigenicity. Endocrinology. 2012 Jul; 153(7):2963-73.
Score: 0.014
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|